Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

After years of preparation, Eli Lilly is on the brink of launching a ... and insulin glargine brand Basaglar. "Despite technological advancements, people continue to experience challenges with ...

Talking about the impact of Donald Trump’s tariff terror on Indian pharma companies, Khorakiwala believes that Indian ...

Eli Lilly’s big-selling insulin ... Approved at the beginning of 2016, US revenues of the cheaper competitor, Basaglar, were around $115 million in Q3, almost double the previous quarter ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.